Effects of class I heparin binding growth factor and fibronectin on platelet adhesion and aggregation.
Fibronectin and heparin binding growth factor-type 1 have been affixed to vascular graft surfaces to enhance the attachment and the proliferation of transplanted endothelial cells, respectively. The current study examines the effect of fibronectin and heparin binding growth factor-type 1 on platelet adhesion and activation in vivo and on platelet aggregation in vitro. Expanded polytetrafluoroethylene prostheses (5 cm x 4 mm internal diameter) were treated either with fibronectin (n = 9), fibronectin/heparin/heparin binding growth factor-type 1/heparin (n = 12), or neither (n = 13) and were interposed into canine aortoiliac systems bilaterally. Autogenous radiolabeled (Indium 111 oxine, 650 microCi) platelets were injected intravenously before reestablishment of circulation. Perfusion was maintained for 30 minutes, and prostheses were removed with segments of native aorta and distal iliac arteries bilaterally. Specimens were examined for thrombus-free surface area, by gamma well counting for adherent radiolabeled platelets, and by light microscopy and transmission and scanning electron microscopic techniques. Results showed that both the fibronectin and fibronectin/heparin/heparin binding growth factor-type 1/heparin pretreated prostheses contained significantly greater numbers of platelets and adherent radioactivity than did control graft segments when normalized to their ipsilateral iliac arteries. Fibronectin/heparin/heparin binding growth factor-type 1/heparin pretreated prostheses contained 27 +/- 16 times more radioactivity per square millimeter than ipsilateral iliac arteries, fibronectin pretreated prostheses had 13 +/- 8 times more radioactivity per square millimeter than ipsilateral iliac arteries, and untreated expanded polytetrafluoroethylene had 4 +/- 3 times more radioactivity per square millimeter than ipsilateral iliac arteries. Fibronectin/heparin/heparin binding growth factor-type 1/heparin was more radioactive than fibronectin alone (p = 0.056). Histologic evaluation and thrombus-free surface area determinations corroborated the gamma well counting data. Platelet aggregation in vitro was not activated by either fibronectin (1 to 100 micrograms/100 microliters) or heparin binding growth factor-type 1 (25 to 2500 ng/100 microliters). These data suggest that fibronectin and heparin binding growth factor-type 1 promote platelet adhesion not aggregation.
Loyola University Medical Center Department of Surgery, Maywood, IL 60153.
H P
HP
Greisler
J J
JJ
Klosak
S J
SJ
Steinam
T M
TM
Lam
W H
WH
Burgess
D U
DU
Kim
D000818:Animals; D001011:Aorta; D001792:Blood Platelets / Q000187:drug effects / Q000648:ultrastructure; D001807:Blood Vessel Prosthesis; D004285:Dogs; D004730:Endothelium, Vascular / Q000166:cytology; D016220:Fibroblast Growth Factor 1; D005353:Fibronectins / Q000494:pharmacology*; D006133:Growth Substances / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D007083:Iliac Artery; D007205:Indium Radioisotopes; D008855:Microscopy, Electron, Scanning; D009942:Organometallic Compounds; D015125:Oxyquinoline / Q000031:analogs & derivatives; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D011138:Polytetrafluoroethylene; D014654:Vascular Patency
D005353:Fibronectins; D006133:Growth Substances; D007205:Indium Radioisotopes; D009942:Organometallic Compounds; D016220:Fibroblast Growth Factor 1; C032950:indium oxine; D015125:Oxyquinoline; D011138:Polytetrafluoroethylene; D006493:Heparin